Evidence map›Paper›PMID 31467441›Full record

ArticleScientific reports2019

Estimating the immunogenicity of measles-rubella vaccination administered during a mass campaign in Lao People's Democratic Republic using multi-valent seroprevalence data.

Emilia Vynnycky, Shinsuke Miyano, Katsuhiro Komase, Yoshio Mori, Makoto Takeda, Tomomi Kitamura, Anonh Xeuatvongsa, Masahiko Hachiya

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Emilia VynnyckyModelling and Economics Unit, Public Health England, 61 Colindale Avenue, Colindale, NW9 5HT, London, UK. Emilia.vynnycky@phe.gov.uk.
Shinsuke MiyanoBureau of International Health Cooperation, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku, Tokyo, 162-8655, Japan.
Katsuhiro KomaseDepartment of Virology III, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musaashi-Murayama, Tokyo, 208-0011, Japan.
Yoshio MoriDepartment of Virology III, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musaashi-Murayama, Tokyo, 208-0011, Japan.
Makoto TakedaDepartment of Virology III, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musaashi-Murayama, Tokyo, 208-0011, Japan.ORCID http://orcid.org/0000-0002-8194-7727
Tomomi KitamuraBureau of International Health Cooperation, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku, Tokyo, 162-8655, Japan.ORCID http://orcid.org/0000-0002-7956-4751
Anonh XeuatvongsaMinistry of Health, National Immunization Program, Simeuang Road, Vientiane, Lao PDR.
Masahiko HachiyaBureau of International Health Cooperation, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku, Tokyo, 162-8655, Japan.
National Center for Global Health and Medicine · JPNational Institute of Infectious Diseases · JPUniversity of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measles and rubella are important causes of morbidity and mortality globally. Despite high coverage reported for measles vaccination, outbreaks continue to occur in some countries. The reasons for these outbreaks are poorly understood. We apply Bayesian methods to multi-valent seroprevalence data for measles and rubella, collected 2 years and 3 months after a mass measles-rubella vaccination campaign in Lao PDR to estimate the immunogenicity and vaccination coverage. When the vaccination coverage was constrained to exceed 95% or 90%, consistent with officially-reported values, the immunogenicity of the measles vaccine component was unexpectedly low (75% (95% CR: 63-82%) and 79% (CR: 70-87%) respectively. The estimated immunogenicity increased after relaxing constraints on the vaccination coverage, with best-fitting values of 83% (95% CR: 73-91%) and 97% (95% CR: 90-100%) for the measles and rubella components respectively, with an estimated coverage of 83% (95% CR: 80-88%). The findings suggest that, if the vaccine coverage was as high as that reported, continuing measles outbreaks in Lao PDR, and potentially elsewhere, may be attributable to suboptimal immunogenicity attained in mass campaigns. Vaccine management in countries with high reported levels of coverage and ongoing measles outbreaks needs to be reviewed if measles elimination targets are to be achieved.

Indexed as

Health PromotionAdolescentChildFemaleHumansLaosMaleMeasles VaccineRubella VaccineSeroepidemiologic StudiesSurveys and QuestionnairesVaccination CoverageYoung AdultMeasles VaccineRubella Vaccine

Identifiers

PMID31467441
PMCPMC6715652
OpenAlexW2970570916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.